BUILDING PARTNERSHIPS

Business Development

Assertio’s strategic goals involve in-licensing and acquiring assets to increase our presence in orphan diseases and other specialty areas. In collaborating with our partners, we aim to benefit both parties while building a portfolio that addresses the needs of patients, physicians, and payers alike.

Assertio is primarily interested in late-stage and on-market therapeutics in specialty areas outside of primary care. Our goal is to identify the deal structure that optimizes return and allows both parties to meet their respective needs. Opportunities include:

  • Targeted acquisitions
  • In-licensing partnerships
  • Commercialization partnerships
  • Other investments and partnerships

OUR PARTNERS

Assertio is experienced in forming and managing a variety of innovative partnerships and deal structures. These include:

  • Collegium Pharmaceutical
    Maximized the potential for Assertio’s Nucynta (tapentadol) franchise by entering into a commercialization agreement with Collegium who is committed to being the leader in responsible pain management.
  • Ironwood
    A license agreement to grant Ironwood worldwide rights to Assertio’s Acuform drug delivery technology for their adjunctive treatment to proton pump inhibitors for patients suffering from persistent gastroesophageal reflux disease.
  • Slan Medical Holdings Ltd
    Licensed the development and commercialization rights to cosyntropin (Synthetic ACTH Depot) in the United States to accelerate the market availability of an alternative long acting ACTH therapy.
  • Applied Pharma Research
    Licensed the drug delivery technology and intellectual property to Cambia (diclofenac potassium for oral solution) from APR and collaborated to formulate a new life cycle extension.
  • PDL Inc.
    Divested the interests in royalties and milestone payments from Merck, Janssen, Boehringer Ingelheim, LG, and Valeant (Santarus).
  • NES Therapeutics
    Provided a capital infusion in return for an equity stake in NES in order to fund the development of a late stage product for a rare life-threatening pediatric infection without an approved treatment.